How echinoccocosis affects potential cancer markers in plasma: Galectin-3, sN-cadherin and sE-cadherin? A preliminary report

Diagnostic Pathology

Volumn 7, Issue 1, 2012, Pages

  Giebultowicz, Joanna ^a   Polanska Plachta, Malgorzata ^a   Wroczynski, Piotr ^a   Zaborowski, Piotr ^b   Polanski, Jerzy A ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

E cadherin; Echinococcosis; Galectin 3; Liver cancer; N cadherin

Indexed keywords

C REACTIVE PROTEIN; CADHERIN; GALECTIN 3; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; HUMAN; LEUKOCYTE; LIVER; LIVER CELL CARCINOMA; LIVER HYDATID CYST; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; C-REACTIVE PROTEIN; CADHERINS; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; ECHINOCOCCOSIS, HEPATIC; GALECTIN 3; HUMANS; LEUKOCYTES; LIVER; LIVER NEOPLASMS; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84857004757     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-7-17     Document Type: Article

References (30)

1. Moro P, Schantz PM. Echinococcosis: a review. Int J Infect Dis 2009, 13:125-133. 10.1016/j.ijid.2008.03.037, 18938096.
2. Reiter-Owona I, Grüner B, Frosch M, Hoerauf A, Kern P, Tappe D. Serological confirmatory testing of alveolar and cystic echinococcosis in clinical practice: results of a comparative study with commercialized and in-house assays. Clin Lab 2009, 55:41-48.
3. Derycke L, De Wever O, Stove V, Vanhoecke B, Delanghe J, Depypere H. M B: Soluble N-cadherin in human biological fluids. Int J Cancer 2006, 119:2895-2900. 10.1002/ijc.22219, 16998833.
4. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E. Concentrations of Galectin-3 in the Sera of Normal Controls and < p > Cancer Patients. Clin Cancer Res 2000, 6:1389-1393.
5. Weiss JV, Klein-Scory S, Kübler S, Reinacher-Schick A, Stricker I, Schmiegel W, Schwarte-Waldhoff I. Soluble E-cadherin as a serum biomarker candidate: Elevated levels in patients with late-stage colorectal carcinoma and FAP. Int J Cancer 2011, 128:1384-1392. 10.1002/ijc.25438, 20473926.
6. Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN, Schnitzbauer A, Schaffler A, Aslanidis C, Scholmerich J, Buechler C. Serum Galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 2010, 95:1404-1411. 10.1210/jc.2009-1619, 20080851.
7. Lin YH, Lin LY, Wu YW, Chien KL, Lee CM, Hsu RB, Chao CL, Wang SS, Hsein YC, Liao LC, et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009, 409:96-99. 10.1016/j.cca.2009.09.001, 19747906.
8. de Boer R, van Veldhuisen DJ. Galectin-3 in Cardiac Remodeling and Heart Failure. Curr Heart Fail Rep 2010, 7:1-8. 10.1007/s11897-010-0004-x, 2831188, 20425490.
9. Matsuda Y, Yamagiwa Y, Fukushima K, Ueno Y, Shimosegawa T. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res 2008, 38:1098-1111. 10.1111/j.1872-034X.2008.00387.x, 18684128.
10. Noë V, Fingleton B, Jacobs K, Crawford H, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001, 114:111-118.
11. Hayashido Y, Hamana T, Yoshioka Y, Kitano H, Koizumi K, Okamoto T. Plasminogen activator/plasmin system suppresses cell-cell adhesion of oral squamous cell carcinoma cells via proteolysis of E-cadherin. Int J Oncol 2005, 27:693-698.
12. Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F, Proksch E, de Strooper B, Hartmann D, Saftig P. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci USA 2005, 102:9182-9187. 10.1073/pnas.0500918102, 1166595, 15958533.
13. Najy AJ, Day KC, Day ML. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem 2008, 283:18393-18401. 10.1074/jbc.M801329200, 2440598, 18434311.
14. Reiss K, Maretzky T, Ludwig A, Tousseyn T, de Strooper B, Hartmann D, Saftig P. ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. EMBO J 2005, 24:742-752. 10.1038/sj.emboj.7600548, 549617, 15692570.
15. Covington MD, Burghardt RC, Parrish AR. Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14). Am J Physiol Renal Physiol 2006, 290:F43-F51.
16. Monea S, Jordan BA, Srivastava S, DeSouza S, Ziff EB. Membrane localization of membrane type 5 matrix metalloproteinase by AMPA receptor binding protein and cleavage of cadherins. J Neurosci 2006, 26:2300-2312. 10.1523/JNEUROSCI.3521-05.2006, 16495457.
17. Dwivedi A, Slater SC, George SJ. MMP-9 and -12 cause N-cadherin shedding and thereby beta-catenin signalling and vascular smooth muscle < p > cell proliferation. Cardiovasc Res 2009, 81:178-186. 10.1093/cvr/cvn278, 18852254.
18. Uemura K, Kihara T, Kuzuya A, Okawa K, Nishimoto T, Ninomiya H, Sugimoto H, Kinoshita A, Shimohama S. Characterization of sequential N-cadherin cleavage by ADAM10 and PS1. Neurosci Lett 2006, 402:278-283. 10.1016/j.neulet.2006.04.018, 16687212.
19. Marco M, Baz A, Fernandez C, Gonzalez G, Hellman U, Salinas G, Nieto A. A relevant enzyme in granulomatous reaction, active matrix metalloproteinase-9, found in bovine Echinococcus granulosus hydatid cyst wall and fluid. Parasitol Res 2006, 100:131-139. 10.1007/s00436-006-0237-5, 16858614.
20. Puxbaum V, Mach L. Proteinases and their inhibitors in liver cancer. World J Hepatol 2009, 1:28-34. 10.4254/wjh.v1.i1.28, 2998952, 21160962.
21. Chan AOO, Lam SK, Chu KM, Lam CM, Kwok E, Leung SY, Yuen ST, Law SYK, Hui WM, Lai KC, et al. Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut 2001, 48:808-811. 10.1136/gut.48.6.808, 1728335, 11358900.
22. Shariat SF, Matsumoto K, Casella R, Lerner SP. Urinary levels of soluble E-Cadherin in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol 2005, 48:69-76. 10.1016/j.eururo.2005.02.012, 15967254.
23. Charalabopoulos K, Gogali A, Dalavaga Y, Daskalopoulos G, Vassiliou M, Bablekos G, Karakosta A, Constantopoulos S. The clinical significance of soluble E-cadherin in nonsmall cell lung cancer. Exp Oncol 2006, 28:83-85.
24. Billion K, Ibrahim H, Mauch C, Niessen CM. Increased soluble E-cadherin in melanoma patients. Skin Pharmacol Physiol 2006, 19:65-70. 10.1159/000091972, 16685144.
25. Soyama A, Eguchi S, Takatsuki M, Kawashita Y, Hidaka M, Tokai H, Nagayoshi S, Mochizuki S, Matsumoto S, Hamasaki K, et al. Significance of the serum level of soluble E-cadherin in patients with HCC. Hepatogastroenterology 2008, 55:1390-1393.
26. Jovov B, Que J, Tobey NA, Djukic Z, Hogan BL, Orlando RC. Role of E-cadherin in the Pathogenesis of Gastroesophageal Reflux Disease. Am J Gastroenterol 2011, 106:1039-1047. 10.1038/ajg.2011.102, 21448147.
27. Pittard AJ, Banks RE, Galley HF, Webster NR. Soluble E-cadherin concentrations in patients with systemic inflammatory response syndrome and multiorgan dysfunction syndrome. Br J Anaesth 1996, 76:629-631.
28. Fu C, Lang J. Serum soluble E-cadherin level in patients with endometriosis. Chin Med Sci J 2002, 17:121-123.
29. Sewpaul A, French JJ, Khoo TK, Kernohan M, Kirby JA, Charnley RM. Soluble E-cadherin: an early marker of severity in acute pancreatitis. Book Soluble E-cadherin: an early marker of severity in acute pancreatitis 2009, City, (Editor ed.^eds.).
30. Monteiro KM, de Carvalho MO, Zaha A, Ferreira HB. Proteomic analysis of the Echinococcus granulosus metacestode during infection of its intermediate host. Proteomics 2010, 10:1985-1999. 10.1002/pmic.200900506, 20217864.